Literature DB >> 890693

Uptake of labeled dianhydrogalactitol into human gliomas and nervous tissue.

S Eckhardt, J Csetényi, I P Horváth, S Kerpel-Fronius, I Számel, L Institóris, F Szlovik, E Pásztor, D Afra.   

Abstract

The distribution of iv administered 3H-dianhydrogalactitol (DAG) in the plasma, cerebrospinal fluid (CSF), brain, and tumor tissue was studied in 11 patients. DAG entered the CSF and was slowly eliminated, with a half-life of 20 hours. Unchanged DAG accounted for about 6%-30% of the total radioactivity in the CSF. All the tumors accumulated the drug to a higher extent than the intact white matter, except the one meningioma studied. The highest uptake was observed in the relatively benign astrocytic tumors.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 890693

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  6 in total

1.  1,2:5,6-dianhydrogalactitol inhibits human glioma cell growth in vivo and in vitro by arresting the cell cycle at G2/M phase.

Authors:  Chun Peng; Xin-Ming Qi; Ling-Ling Miao; Jin Ren
Journal:  Acta Pharmacol Sin       Date:  2017-02-20       Impact factor: 6.150

Review 2.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

3.  Chemotherapeutic approaches to brain tumors. Experimental observations with dianhydrogalactitol and dibromodulcitol.

Authors:  V A Levin; K T Wheeler
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Dianhydrogalactitol synergizes with topoisomerase poisons to overcome DNA repair activity in tumor cells.

Authors:  Beibei Zhai; Yue Li; Sudha Sravanti Kotapalli; Jeffrey Bacha; Dennis Brown; Anne Steinø; Mads Daugaard
Journal:  Cell Death Dis       Date:  2020-07-24       Impact factor: 8.469

5.  Inhibition of DNA Repair in Combination with Temozolomide or Dianhydrogalactiol Overcomes Temozolomide-Resistant Glioma Cells.

Authors:  Shigeo Ohba; Kei Yamashiro; Yuichi Hirose
Journal:  Cancers (Basel)       Date:  2021-05-24       Impact factor: 6.639

6.  Dianhydrogalactitol induces replication-dependent DNA damage in tumor cells preferentially resolved by homologous recombination.

Authors:  Beibei Zhai; Anne Steinø; Jeffrey Bacha; Dennis Brown; Mads Daugaard
Journal:  Cell Death Dis       Date:  2018-10-03       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.